Coherus Biosciences (CHRS)
NASDAQ:CHRS
Total Valuation
Coherus Biosciences has a market cap or net worth of $250.32M. The enterprise value is $150.60M.
Market Cap$250.32M
Enterprise Value$150.60M
Share Statistics
Coherus Biosciences has 149,889,910 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding149,889,910
Owned by Insiders1.14%
Owned by Institutions9.45%
Financial Efficiency
Coherus Biosciences’s return on equity (ROE) is -2.79 and return on invested capital (ROIC) is -153.12%.
Return on Equity (ROE)-2.79
Return on Assets (ROA)-0.66
Return on Invested Capital (ROIC)-153.12%
Return on Capital Employed (ROCE)-1.56
Revenue Per Employee184.96K
Profits Per Employee736.95K
Employee Count228
Asset Turnover0.16
Inventory Turnover4.35
Valuation Ratios
The current PE Ratio of Coherus Biosciences is ―. Coherus Biosciences’s PEG ratio is 0.00148.
PE Ratio―
PS Ratio4.05
PB Ratio2.80
Price to Fair Value2.80
Price to FCF-1.23
Price to Operating Cash Flow-1.45
PEG Ratio0.00148
Income Statement
In the last 12 months, Coherus Biosciences had revenue of 42.17M and earned -170.29M in profits. Earnings per share was -1.45.
Revenue42.17M
Gross Profit28.36M
Operating Income-181.13M
Pretax Income-183.12M
Net Income-170.29M
EBITDA-170.20M
Earnings Per Share (EPS)-1.45
Cash Flow
In the last 12 months, operating cash flow was -138.51M and capital expenditures 0.00, giving a free cash flow of -138.51M billion.
Operating Cash Flow-138.51M
Free Cash Flow-138.51M
Free Cash Flow per Share-0.92
Dividends & Yields
Coherus Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.26
52-Week Price Change114.11%
50-Day Moving Average1.83
200-Day Moving Average1.42
Relative Strength Index (RSI)47.96
Average Volume (3m)1.26M
Important Dates
Coherus Biosciences upcoming earnings date is Apr 30, 2026, After Close (Confirmed).
Last Earnings DateMar 9, 2026
Next Earnings DateApr 30, 2026
Ex-Dividend Date―
Financial Position
Coherus Biosciences as a current ratio of 1.46, with Debt / Equity ratio of 66.11%
Current Ratio1.46
Quick Ratio1.43
Debt to Market Cap0.22
Net Debt to EBITDA0.29
Interest Coverage Ratio-20.12
Taxes
In the past 12 months, Coherus Biosciences has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Coherus Biosciences EV to EBITDA ratio is -0.72, with an EV/FCF ratio of -0.88.
EV to Sales2.90
EV to EBITDA-0.72
EV to Free Cash Flow-0.88
EV to Operating Cash Flow-0.88
Balance Sheet
Coherus Biosciences has $172.13M in cash and marketable securities with $40.34M in debt, giving a net cash position of $131.79M billion.
Cash & Marketable Securities$172.13M
Total Debt$40.34M
Net Cash$131.79M
Net Cash Per Share$0.88
Tangible Book Value Per Share$0.12
Margins
Gross margin is 67.24%, with operating margin of -429.51%, and net profit margin of -403.80%.
Gross Margin67.24%
Operating Margin-429.51%
Pretax Margin-434.23%
Net Profit Margin-403.80%
EBITDA Margin-403.58%
EBIT Margin-412.89%
Analyst Forecast
The average price target for Coherus Biosciences is $7.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$7.00
Price Target Upside319.16% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast-72.54%
EPS Growth Forecast-19972.15%